Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | MAP2 | P11137 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24855441 | 0.86 | ALDH1A1 (0.38) | TSHRENPP2IDO1ALDH1A1CYP3A4 | |
| SCHEMBL26366492 | 0.84 | ERN1 (0.37) | ERN1 | |
| SCHEMBL29180725 | 0.80 | ERN1 (0.42) | ENPP2CYP3A4ERN1 | |
| SCHEMBL1359177 | 0.78 | ERN1 (0.39) | ALDH1A1ERN1 | |
| SCHEMBL28824846 | 0.76 | ENPP2 (0.33) | TSHRENPP2ALDH1A1 | |
| SCHEMBL15149395 | 0.76 | CA12 (0.41) | ENPP2 | |
| SCHEMBL16687785 | 0.74 | SELL (0.38) | ALDH1A1ERN1 | |
| SCHEMBL24492688 | 0.74 | TTR (0.32) | — | |
| SCHEMBL3322062 | 0.74 | TSHR (0.35) | TSHRCYP3A4 | |
| SCHEMBL3586689 | 0.73 | IDO1 (0.34) | IDO1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087634-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4727934-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024260929-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-26 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114736243-A | Organic luminescent material and application | 北京燕化集联光电技术有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-9663506-B2 | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663506-B2 | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9636337-B2 | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9636337-B2 | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160158217-A1 | Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159744-A1 | Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9278960-B2 | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278960-B2 | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140309227-A1 | QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME LLC | 2014-10-16 | — | — | US | disclosed |
| US-20140309227-A1 | QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME LLC | 2014-10-16 | — | — | US | disclosed |
| EP-2616071-A2 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2013-07-04 | — | — | US | disclosed |
| WO-2013066736-A1 | QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2012037299-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159744-A1 | Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use | GRIN2A, GRIA2, GRIN2B | TSHR 1048/4885ENPP2 590/4885IDO1 3455/4885 |
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | TSHR 2274/4885ENPP2 904/4885IDO1 1837/4885 |
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | TSHR 122/4885ENPP2 13/4885IDO1 150/4885 |
| US-20160158217-A1 | Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use | GRIN2A, GRIA2, GRIN2B | TSHR 1048/4885ENPP2 590/4885IDO1 3455/4885 |
| US-20140309227-A1 | QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | GRIN2A, GRIA2, GRIN2B | TSHR 1070/4885ENPP2 580/4885IDO1 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.